KalVista CMO granted 100,000 RSUs

KalVista Pharmaceuticals’ chief medical officer receives new equity award.

Rhea-AI Filing Summary

KalVista Pharmaceuticals’ chief medical officer receives new equity award. Paul K. Audhya, the company’s Chief Medical Officer, reported a grant of 100,000 restricted stock units on January 16, 2026. Each RSU represents the right to receive 1 share of KalVista common stock upon settlement for no cash payment. The RSUs will vest over four years, with 1/16 of the total units vesting on each quarterly anniversary of the vesting commencement date, starting on May 22, 2026, as long as his service with the company continues. Following this grant, he beneficially owns 100,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Audhya Paul K.

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	100,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 100,000 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
2. F2. 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 22, 2026, for so long as grantee's Service (as defined in the Plan) does not terminate.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KalVista (KALV) report in this Form 4?

The filing reports that Chief Medical Officer Paul K. Audhya received a grant of 100,000 restricted stock units (RSUs) on January 16, 2026.

How do the new RSUs for KalVista (KALV) work?

Each RSU gives Dr. Audhya a contingent right to receive 1 share of KalVista common stock upon settlement for no cash consideration.

What is the vesting schedule for the 100,000 RSUs at KalVista (KALV)?

The 100,000 RSUs vest in 16 equal installments, with 1/16 of the units vesting on each quarterly anniversary of the vesting commencement date, starting on May 22, 2026, as long as his service continues.

How many derivative securities does the KalVista (KALV) CMO own after this transaction?

After the grant, Dr. Audhya beneficially owns 100,000 derivative securities (RSUs), held directly.

Was the KalVista (KALV) Form 4 transaction a purchase or sale of stock?

No cash purchase or sale of stock is reported. The Form 4 reflects an award of 100,000 RSUs that may convert into shares of common stock over time as they vest.

Who is the reporting person in this KalVista (KALV) Form 4 filing?

The reporting person is Paul K. Audhya, who serves as Chief Medical Officer of KalVista Pharmaceuticals, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Audhya Paul K.

(Last) (First) (Middle)

C/O KALVISTA PHARMACEUTICALS, INC.

200 CROSSING BOULEVARD

(Street)

FRAMINGHAM MA 01702

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KalVista Pharmaceuticals, Inc. [ KALV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	01/16/2026		A		100,000		(2)	(2)	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 22, 2026, for so long as grantee's Service (as defined in the Plan) does not terminate.

	/s/ Benjamin L. Palleiko, Attorney-in-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.